Business Context and Reporting Period
This Form 8-K is a current report filed by PharmAthene, Inc. (not Altimmune, Inc.) on November 9, 2011. The filing serves to announce the company's financial and operating results for the quarter ended September 30, 2011. The detailed results are contained in a press release furnished as Exhibit 99.1.
Key Financial Metrics
The provided text is a cover sheet and does not contain specific financial data. The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. These figures are referenced as being available in the attached press release (Exhibit 99.1), which is not included in the input content.
Material Changes
No material changes or comparative financial data are disclosed within the text of this Form 8-K. The document solely references the issuance of the quarterly results announcement.
Guidance, Outlook, and Risks
The filing includes a standard disclaimer in accordance with General Instruction B.2 of Form 8-K. It states that the information in this report, including the press release, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not subject to the liabilities of that section. No specific guidance, outlook, or risk factors are detailed in the provided text.
Investor Verification Checklist
- Verify the actual financial figures (revenue, net loss, cash position) by reviewing the press release attached as Exhibit 99.1, as they are absent from this summary text.
- Confirm the company name is PharmAthene, Inc., noting the discrepancy with the "Altimmune, Inc." label in the request metadata.
- Review the full press release for any forward-looking statements or operational updates regarding the quarter ended September 30, 2011.